Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?

BMC Medicine

Mikael Rabaeus²  Pascal Defaye³  Patricia Salen¹  Michel de Lorgeril¹ 

[1] Laboratoire Cœur et Nutrition, TIMC-IMAG CNRS 5525, Université Joseph Fourier, Faculté de Médecine de Grenoble, 38054 La Tronche, France;Clinique La Prairie, Chemin de la Prairie 2-10, 1815 Clarens, Montreux, Switzerland;Service de Cardiologie, Hôpital Universitaire Nord, 38054 La Tronche, France

关键词: n-6 fatty acids;    diabetes;    insulin resistance;    mitochondria;    epidemiology;    randomized clinical trials;    myocardial infarction;    ischemic heart disease;    statins;    omega-3 fatty acids;   

Others  :  857238
DOI  :  10.1186/1741-7015-11-5

 received in 2012-07-04, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Early randomized controlled trials (RCTs) demonstrated the health benefits of omega-3 fatty acids (n-3), whereas recent RCTs were negative. We now address the issue, focusing on the temporal changes having occurred: most patients in recent RCTs are no longer n-3 deficient and the vast majority are now treated with statins. Recent RCTs testing n-3 against arrhythmias suggest that n-3 reduce the risk only in patients not taking a statin. Other recent RCTs in secondary prevention were negative although, in a post-hoc analysis separating statin users and non-users, non-significant protection of n-3 was observed among statin non-users whereas statin users had no effect. Recent RCTs testing statins - after the implementation of the New Clinical Trial Regulation in 2007 - are negative (or flawed) suggesting that the lack of effect of n-3 cannot be attributed to a parallel protection by statins. Finally, statins favor the metabolism of omega-6 fatty acids (n-6), which in turn inhibits n-3 and, contrary to n-3, they increase insulin resistance and the risk of diabetes. Thus, n-3 and statins are counteractive at several levels and statins appear to inhibit n-3.

【 授权许可】

   
2013 de Lorgeril et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mozaffarian D, Wu JH: Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
• [2]De Caterina R: n-3 fatty acids in cardiovascular disease. N Engl J Med 2011, 364:2439-2450.
• [3]Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
• [4]Holy EW, Forestier M, Richter EK, Akhmedov A, Leiber F, Camici GG, Mocharla P, Lüscher TF, Beer JH, Tanner FC: Dietary α-linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler Thromb Vasc Biol 2011, 31:1772-1780.
• [5]Zeghichi-Hamri S, de Lorgeril M, Salen P, Chibane M, de Leiris J, Boucher F, Laporte F: Protective effect of dietary n-3 polyunsaturated fatty acids on myocardial resistance to ischemia-reperfusion injury in rats. Nutr Res 2010, 30:849-857.
• [6]Abdukeyum GG, Owen AJ, McLennan PL: Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning. J Nutr 2008, 138:1902-1909.
• [7]Billman GE, Hallaq H, Leaf A: Prevention of ischemia-induced ventricular fibrillation by ω-3 fatty acids. Proc Natl Acad Sci USA 1994, 91:4427-4430.
• [8]Albert CM, Oh K, Whang W, Manson JE, Chae CU, Stampfer MJ, Willett WC, Hu FB: Dietary alpha-linolenic acid intake and risk of sudden cardiac death and coronary heart disease. Circulation 2005, 112:3232-3238.
• [9]Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE: Fish consumption and risk of sudden cardiac death. JAMA 1998, 279:23-28.
• [10]Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effect of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 2:757-761.
• [11]Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Lancet 1999, 354:447-455. Erratum: Lancet 2007, 369:106 and Lancet 2001, 357:642
• [12]de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454-1459.
• [13]de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779-785.
• [14]Mozaffarian D, Rimm EB: Fish intake, contaminants and human health. Evaluating the risks and benefits. JAMA 2006, 296:1885-1899.
• [15]Harris WS, von Schacky C: The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 2004, 39:212-220.
• [16]Harris WS, Sands SA, Windsor SL: Omega-3 fatty acids in cardiac biopsies from heart transplantation patients. Correlation with erythrocytes and response to supplementation. Circulation 2004, 110:1645-1649.
• [17]Sullivan BL, Williams PG, Meyer BJ: Biomarker validation of a long-chain omega-3 polyunsaturated fatty acid food frequency questionnaire. Lipids 2006, 41:845-850.
• [18]Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005, 293:2884-2891.
• [19]Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H, Schoenfeld D, Fatty Acid Antiarrhythmia Trial Investigators: Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005, 112:2762-2768.
• [20]Brouwer IA, Zock PL, Camm AJ, Böcker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H, Schouten EG, SOFA Study Group: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006, 295:2613-2619.
• [21]Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, SU.FOL.OM3 Collaborative Group: Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 341:c6273.
• [22]Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Spitzer W, Sabin G, Senges J, OMEGA Study Group: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
• [23]Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group: n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026.
• [24]Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-Analysis Study Group: Efficacy of omega-3 fatty acid supplements (eicosapentanoic acid and docosahexanoic acid) in the secondary prevention of cardiovascular disease. A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012, 172:686-694.
• [25]Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR, Siscovick DS, Mozaffarian D: Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation 2012, 125:1084-1093.
• [26]Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP: Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009, 120:2315-2321.
• [27]Strøm M, Halldorsson TI, Mortensen EL, Torp-Pedersen C, Olsen SF: Fish, n-3 fatty acids, and cardiovascular diseases in women of reproductive age: a prospective study in a large national cohort. Hypertension 2012, 59:36-43.
• [28]Vedtofte MS, Jakobsen MU, Lauritzen L, Heitmann BL: Dietary α-linolenic acid, linoleic acid, and n-3 long-chain PUFA and risk of ischemic heart disease. Am J Clin Nutr 2011, 94:1097-1103.
• [29]Joensen AM, Overvad K, Dethlefsen C, Johnsen SP, Tjønneland A, Rasmussen LH, Schmidt EB: Marine n-3 polyunsaturated fatty acids in adipose tissue and the risk of acute coronary syndrome. Circulation 2011, 124:1232-1238.
• [30]Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC: Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003, 57:193-200.
• [31]Wilhelm M, Tobias R, Asskali F, Kraehner R, Kuly S, Klinghammer L, Boehles H, Daniel WG: Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am Heart J 2008, 155:971-977.
• [32]Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, Katan MB, Connor WE, Camm JA, Schouten EG, McAnulty J: Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009, 30:820-826.
• [33]Billman GE, Carnes CA, Adamson PB, Vanoli E, Schwartz PJ: Dietary omega-3 fatty acids and susceptibility to ventricular fibrillation: lack of protection and a proarrhythmic effect. Circ Arrhythm Electrophysiol 2012, 5:553-560.
• [34]Coronel R, Wilms-Schopman FJ, Den Ruijter HM, Belterman CN, Schumacher CA, Opthof T, Hovenier R, Lemmens AG, Terpstra AH, Katan MB, Zock P: Dietary n-3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts. Cardiovasc Res 2007, 73:386-394.
• [35]Berecki G, Den Ruijter HM, Verkerk AO, Schumacher CA, Baartscheer A, Bakker D, Boukens BJ, van Ginneken AC, Fiolet JW, Opthof T, Coronel R: Dietary fish oil reduces the incidence of triggered arrhythmias in pig ventricular myocytes. Heart Rhythm 2007, 4:1452-1460.
• [36]Burdge GC, Wootton SA: Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002, 88:411-420.
• [37]Burdge GC, Jones AE, Wootton SA: Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr 2002, 88:355-363.
• [38]Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
• [39]Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D: Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J 2012, 33:1582-1588.
• [40]Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA Lipid Intervention Study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098. Erratum in: Lancet 2007, 370:220
• [41]Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
• [42]Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
• [43]Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
• [44]de Lorgeril M, Salen P, Guiraud A, Zeghichi S, Boucher F, de Leiris J: Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutr Metab Cardiovasc Dis 2005, 15:36-41.
• [45]Risé P, Ghezzi S, Priori I, Galli C: Differential modulation by simvastatin of the metabolic pathways in the n-9, n-6 and n-3 fatty acid series, in human monocytic and hepatocytic cell lines. Biochem Pharmacol 2005, 69:1095-1100.
• [46]Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003, 107:2646-2652.
• [47]Block RC, Harris WS, Reid KJ, Spertus JA: Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J 2008, 156:1117-1123.
• [48]Kashiyama T, Ueda Y, Nemoto T, Wada M, Masumura Y, Matsuo K, Nishio M, Hirata A, Asai M, Kashiwase K, Kodama K: Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J 2011, 75:2432-2438.
• [49]Mozaffarian D, Ascherio A, Hu FB, Stampfer MJ, Willett WC, Siscovick DS, Rimm EB: Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005, 111:157-164.
• [50]Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM: n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr 2010, 104:1586-1600.
• [51]Renaud S, de Lorgeril M: Dietary lipids and their relation to ischaemic heart disease: from epidemiology to prevention. J Intern Med Suppl 1989, 731:39-46.
• [52]Ramsden CE, Hibbeln JR, Majchrzak-Hong SF: All PUFAs are not created equal: absence of CHD benefit specific to linoleic acid in randomized controlled trials and prospective observational cohorts. World Rev Nutr Diet 2011, 102:30-43.
• [53]Murry CE, Jennings RB, Reimer KA: New insights into potential mechanisms of ischemic preconditioning. Circulation 1991, 84:442-445.
• [54]de Lorgeril M, Salen P: New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids. BMC Med 2012, 10:50. BioMed Central Full Text
• [55]Schwartz DR, Sack MN: Targeting the mitochondria to augment myocardial protection. Curr Opin Pharmacol 2008, 8:160-165.
• [56]Correia SC, Cardoso S, Santos RX, Carvalho C, Santos MS, Perry G, Smith MA, Moreira PI: New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection. Curr Pharm Des 2011, 17:3381-3389.
• [57]Khairallah RJ, O'Shea KM, Brown BH, Khanna N, Des Rosiers C, Stanley WC: Treatment with docosahexaenoic acid, but not eicosapentaenoic acid, delays Ca2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther 2010, 335:155-162.
• [58]McMillin JB, Bick RJ, Benedict CR: Influence of dietary fish oil on mitochondrial function and response to ischemia. Am J Physiol 1992, 263:H1479-1485.
• [59]Khairallah RJ, Kim J, O'Shea KM, O'Connell KA, Brown BH, Galvao T, Daneault C, Des Rosiers C, Polster BM, Hoppel CL, Stanley WC: Improved mitochondrial function with diet-induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids. PLoS One 2012, 7:e34402.
• [60]Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S: Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006, 63:2415-2425.
• [61]Littarru GP, Langsjoen P: Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007, 7:S168-174.
• [62]Dai YL, Luk TH, Siu CW, Yiu KH, Chan HT, Lee SW, Li SW, Tam S, Fong B, Lau CP, Tse HF: Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease. Cardiovasc Toxicol 2010, 10:130-138.
• [63]Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, Mercier J: Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012, 259:263-268.
• [64]Murphy MP, Morales J, Beckett TL, Astarita G, Piomelli D, Weidner A, Studzinski CM, Dowling AL, Wang X, Levine H, Kryscio RJ, Lin Y, Barrett E, Head E: Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis 2010, 22:135-150.
• [65]Martin SB, Cenini G, Barone E, Dowling AL, Butterfield DA, Murphy MP, Head E: Coenzyme Q10 and cognition in atorvastatin treated dogs. Neurosci Lett 2011, 501:92-95.
• [66]de Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R: Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999, 33:473-478.
• [67]Newsholme P, Gaudel C, Krause M: Mitochondria and diabetes. An intriguing pathogenetic role. Adv Exp Med Biol 2012, 942:235-247.
• [68]Abdul-Ghani MA, DeFronzo RA: Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 2008, 8:173-178.
• [69]Patti ME, Corvera S: The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010, 31:364-395.
• [70]Maassen JA, Hart LM, Ouwens DM: Lessons that can be learned from patients with diabetogenic mutations in mitochondrial DNA: implications for common type 2 diabetes. Curr Opin Clin Nutr Metab Care 2007, 10:693-697.
• [71]Fernandez G, Spatz ES, Jablecki C, Phillips PS: Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011, 78:393-403.
• [72]Ivy JL: Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Med 1997, 24:321-336.
• [73]Solomon TP, Sistrun SN, Krishnan RK, Del Aguila LF, Marchetti CM, O'Carroll SM, O'Leary VB, Kirwan JP: Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 2008, 104:1313-1319.
• [74]Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
• [75]Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y: Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152.
• [76]Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
• [77]Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
• [78]Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
• [79]Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841. Erratum: N Engl J Med 2011, 364:1281
• [80]Brostow DP, Odegaard AO, Koh WP, Duval S, Gross MD, Yuan JM, Pereira MA: Omega-3 fatty acids and incident type 2 diabetes: the Singapore Chinese Health Study. Am J Clin Nutr 2011, 94:520-526.
• [81]Villegas R, Xiang YB, Elasy T, Li HL, Yang G, Cai H, Ye F, Gao YT, Shyr Y, Zheng W, Shu XO: Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. Am J Clin Nutr 2011, 94:543-551.
• [82]Djoussé L, Gaziano JM, Buring JE, Lee IM: Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr 2011, 93:143-150.
• [83]Patel PS, Forouhi NG, Kuijsten A, Schulze MB, van Woudenbergh GJ, Ardanaz E, Amiano P, Arriola L, Balkau B, Barricarte A, Beulens JW, Boeing H, Buijsse B, Crowe FL, de Lauzon-Guillan B, Fagherazzi G, Franks PW, Gonzalez C, Grioni S, Halkjaer J, Huerta JM, Key TJ, Kühn T, Masala G, Nilsson P, Overvad K, Panico S, Quirós JR, Rolandsson O, Sacerdote C, et al.: The prospective association between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct Study. Am J Clin Nutr 2012, 95:1445-1453.
• [84]Feskens EJ: The prevention of type 2 diabetes: should we recommend vegetable oils instead of fatty fish? Am J Clin Nutr 2011, 94:369-370.
• [85]Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
• [86]Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, Iida K, Choquet H, Besnard P, Lecoeur C, Vivequin S, Ayukawa K, Takeuchi M, Ozawa K, Tauber M, Maffeis C, Morandi A, Buzzetti R, Elliott P, Pouta A, Jarvelin MR, Körner A, Kiess W, Pigeyre M, Caiazzo R, Van Hul W, Van Gaal L, et al.: Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012, 483:350-354.
• [87]Patel PS, Sharp SJ, Jansen E, Luben RN, Khaw KT, Wareham NJ, Forouhi NG: Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. Am J Clin Nutr 2010, 92:1214-1222.
• [88]Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A: Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: systematic review and meta-analysis of prospective studies. Diabetes Care 2012, 35:918-929.
• [89]Ibrahim MM, Fjære E, Lock EJ, Naville D, Amlund H, Meugnier E, Le Magueresse Battistoni B, Frøyland L, Madsen L, Jessen N, Lund S, Vidal H, Ruzzin J: Chronic consumption of farmed salmon containing persistent organic pollutants causes insulin resistance and obesity in mice. PLoS One 2011, 6:e25170.
• [90]Lee HK, Cho YM, Kwak SH, Lim S, Park KS, Shim EB: Mitochondrial dysfunction and metabolic syndrome-looking for environmental factors. Biochim Biophys Acta 2010, 1800:282-289.
• [91]Ruzzin J, Petersen R, Meugnier E, Madsen L, Lock EJ, Lillefosse H, Ma T, Pesenti S, Sonne SB, Marstrand TT, Malde MK, Du ZY, Chavey C, Fajas L, Lundebye AK, Brand CL, Vidal H, Kristiansen K, Frøyland L: Persistent organic pollutant exposure leads to insulin resistance syndrome. Environ Health Perspect 2010, 118:465-471.
• [92]Lim S, Cho YM, Park KS, Lee HK: Persistent organic pollutants, mitochondrial dysfunction, and metabolic syndrome. Ann N Y Acad Sci 2010, 1201:166-176.
• [93]Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM: Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
• [94]Golomb BA, Evans MA, Dimsdale JE, White HL: Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012, 13:1180-1182.
• [95]Sydenham E, Dangour AD, Lim WS: Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 2012, 6:CD005379.
• [96]Dangour AD, Andreeva VA, Sydenham E, Uauy R: Omega 3 fatty acids and cognitive health in older people. Br J Nutr 2012, 107(Suppl 2):S152-158.
• [97]Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
• [98]Spector R, Snapinn SM: Statins for secondary prevention of cardiovascular disease: the right dose. Pharmacology 2011, 87:63-69.
• [99]Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:b2376.
• [100]Blaha MJ, Nasir K, Blumenthal RS: Statin therapy for healthy men identified as "increased risk". JAMA 2012, 307:1489-1490.
• [101]O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142-1426.
• [102]Hayward RA, Krumholz HM: Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012, 5:2-5.
• [103]Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD004816.
• [104]Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M: Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010, 138:25-31.
• [105]Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB: Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012, 59:572-582.
• [106]Gutierrez J, Ramirez G, Rundek T, Sacco RL: Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012, 172:909-919.
• [107]Redberg RF: Don't assume women are the same as men: include them in the trial: include more women in clinical trials. Arch Intern Med 2012, 172:921.
• [108]Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statin-related adverse events: a meta-analysis. Clin Ther 2006, 28:26-35.
• [109]Meador BM, Huey K: Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010, 42:469-479.
• [110]Baer AN, Wortmann RL: Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007, 19:67-73.
• [111]Goldfine AB: Statins: is it really time to reassess benefits and risks? N Engl J Med 2012, 366:1752-1755.
• [112]Hoffman KB, Kraus C, Dimbil M, Golomb BA: A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 2012, 7:e42866.
• [113]Cham S, Evans MA, Denenberg JO, Golomb BA: Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 2010, 30:541-553.
• [114]Redberg RF, Katz MH: Healthy men should not take statins. JAMA 2012, 307:1491-1492.
• [115]Fellström BC, Jardine AG, Schmieder ME, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
• [116]Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
• [117]Bollapragada SS, Norrie JD, Norman JE: Review of new regulations for the conduct of clinical trials of investigational medicinal products. BJOG 2007, 114:917-921.
• [118]Commission of the European Communities: Commission Directive 2005/28/EC of 8 April 2005. [http:/ / eurlex.europa.eu/ LexUriServ/ LexUriServ.do?uri=OJ:L:2005:091:001 3:0019:en:PDF] webcite
• [119]Topol EJ: Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004, 351:1707-1709.
• [120]Biddle J: Lessons from the Vioxx debacle: what the privatization of science can teach us about social epistemology. Soc Epistemol 2007, 21:21-39.
• [121]Bourgeois FT, Murthy S, Mandl KD: Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010, 153:158-166.
• [122]Chan A-W: Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med 2008, 5:e230.
• [123]Rising K, Bacchetti P, Bero L: Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008, 5:e217.
• [124]Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C, Hébert PC, Kotzin S, Marusic A, Sahni P, Schroeder TV, Sox HC, Van der Weyden MB, Verheugt FW: Clinical trial registration: looking back and moving ahead. JAMA 2007, 298:93-94.
• [125]Mitka M: Controversies surround heart drug study. Questions about Vytorin and trial sponsors' conduct. JAMA 2008, 299:885-887.
• [126]Greenland P, Lloyd-Jones D: Critical lessons from ENHANCE trial. JAMA 2008, 299:953-955.
• [127]Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009, 339:b2942.
• [128]Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. Erratum: N Engl J Med 2007, 357:100
• [129]Fong TM, Heymsfield SB: Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes (Lond) 2009, 33:947-955.
• [130]Sam AH, Salem V, Ghatei MA: Rimonabant: From RIO to Ban. J Obes 2011, 2011:432607.
• [131]Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
• [132]Knopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006, 29:1478-1485.
• [133]de Lorgeril M, Hamazaki T, Kostucki W, Okuyama H, Pavy B, McGill AT, Rabaeus M: Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials 2012, 7:150-157.
• [134]Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, et al.: Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010, 303:1180-1187.
• [135]Cholesterol Treatment Trialists' Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins. Lancet 2008, 371:117-125.
• [136]de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M: Cholesterol-lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. A critical reappraisal. Arch Intern Med 2010, 170:1032-1036.
• [137]de Lorgeril M: Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory? World Rev Nutr Diet 2009, 100:80-89.
• [138]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994, 344:1383-1389.
• [139]Kaul S, Morrissey RP, Diamond GA: By Jove! What is a clinician to make of JUPITER? Arch Intern Med 2010, 170:1073-1077.
• [140]Green LA: Cholesterol-lowering therapy for primary prevention. Still much we don't know. Arch Intern Med 2010, 170:1007-1008.
• [141]Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N: Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65229 participants. Arch Intern Med 2010, 170:1024-1031.
• [142]Memorandum from the DMEP of the US FDA. Advisory Committee meeting for Rosuvastatin 12 November 2009 [http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831.pdf webcite] Accessed September 4, 2012
• [143]Advisory Committee of the US FDA for rosuvastatin December 2009 [http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM194918.pdf webcite] Accessed September 4, 2012
• [144]Ridker PM, Glynn RJ: The JUPITER Trial: responding to the critics. Am J Cardiol 2010, 106:1351-1356.
• [145]Ridker PM: The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes 2009, 2:279-285.
• [146]Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE: Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
• [147]Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF: Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:263-275.
• [148]Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM: Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:251-262.
• [149]Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170.
• [150]Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
• [151]Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
• [152]Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS: Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.
• [153]The ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318.
• [154]Lifestyle Changes and Prevention of Heart Attack [http://www.heart.org/HEARTORG/Conditions/HeartAttack/PreventionTreatmentofHeartAttack/Lifestyle-Changes_UCM_303934_Article.jsp webcite] Accessed September 4, 2012
• [155]Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16-22.